| Name | Title | Contact Details |
|---|
Possis Medical, Inc. is a developer, manufacturer and marketer of medical devices, operating in one business segment.
NeuroVision is developing a noninvasive, quick, and inexpensive retinalimaging test for the early detection and diagnosis of Alzheimer`s disease.
BI Nutraceuticals is a solutions-based botanical manufacturer, custom contract manufacturer, and supplier to the Dietary Supplement, Food & Beverage, Pharmaceutical, Personal Care, and Pet Care Industries. We are the leading manufacturer of whole herb powders and teas, standardized and drug ratio extracts, vitamins, minerals, amino acids, custom blends, drum-to-hopper (D-T-H) formulations, and granular ingredients. BI Nutraceuticals is committed to providing top-quality ingredients, starting even before the raw material comes through the door with our in-depth industry knowledge and distinguished vendor qualification program. The moment we receive the material it undergoes BI`s Protexx HP™ Green Steam™ sterilization, our patented high pressure, low moisture steam sterilization process, and a complete array of tests including Identilok®, our proprietary Species Genus identificaiton technology. The result is a product that meets a quality standard above all others. Quality is our competitive differentiator and the single most important ingredient we sell.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
Solaris-Newtech, is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.